Cargando…
Molecular Logic as a Means to Assess Therapeutic Antidotes
An emerging direction in the area of molecular logic and computation is developing molecular-scale devices that can operate in complex biological environments, such as within living cells, which are beyond the reach of conventional electronic devices. Herein we demonstrate, at the proof-of-principle...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499185/ https://www.ncbi.nlm.nih.gov/pubmed/31106191 http://dx.doi.org/10.3389/fchem.2019.00243 |
_version_ | 1783415757098450944 |
---|---|
author | Unger-Angel, Linor Motiei, Leila Margulies, David |
author_facet | Unger-Angel, Linor Motiei, Leila Margulies, David |
author_sort | Unger-Angel, Linor |
collection | PubMed |
description | An emerging direction in the area of molecular logic and computation is developing molecular-scale devices that can operate in complex biological environments, such as within living cells, which are beyond the reach of conventional electronic devices. Herein we demonstrate, at the proof-of-principle level, how concepts applied in the field of molecular logic gates can be used to convert a simple fluorescent switch (YES gate), which lights up in the presence of glutathione s-transferase (GST), into a medicinally relevant INHIBIT gate that responds to both GST and beta-cyclodextrin (β-CD) as input signals. We show that the optical responses generated by this device indicate the ability to use it as an enzyme inhibitor, and more importantly, the ability to use β-CD as an “antidote” that prevents GST inhibition. The relevance of this system to biomedical applications is demonstrated by using the INHIBIT gate and β-CD to regulate the growth of breast cancer cells, highlighting the possibility of applying supramolecular inputs, commonly used to control the fluorescence of molecular logic gates, as antidotes that reverse the toxic effect of chemotherapy agents. We also show that the effect of β-CD can be prevented by introducing 1-adamantanecarboxylic acid (Ad-COOH) as an additional input signal, indicating the potential of obtaining precise, temporal control over enzyme activity and anticancer drug function. |
format | Online Article Text |
id | pubmed-6499185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64991852019-05-17 Molecular Logic as a Means to Assess Therapeutic Antidotes Unger-Angel, Linor Motiei, Leila Margulies, David Front Chem Chemistry An emerging direction in the area of molecular logic and computation is developing molecular-scale devices that can operate in complex biological environments, such as within living cells, which are beyond the reach of conventional electronic devices. Herein we demonstrate, at the proof-of-principle level, how concepts applied in the field of molecular logic gates can be used to convert a simple fluorescent switch (YES gate), which lights up in the presence of glutathione s-transferase (GST), into a medicinally relevant INHIBIT gate that responds to both GST and beta-cyclodextrin (β-CD) as input signals. We show that the optical responses generated by this device indicate the ability to use it as an enzyme inhibitor, and more importantly, the ability to use β-CD as an “antidote” that prevents GST inhibition. The relevance of this system to biomedical applications is demonstrated by using the INHIBIT gate and β-CD to regulate the growth of breast cancer cells, highlighting the possibility of applying supramolecular inputs, commonly used to control the fluorescence of molecular logic gates, as antidotes that reverse the toxic effect of chemotherapy agents. We also show that the effect of β-CD can be prevented by introducing 1-adamantanecarboxylic acid (Ad-COOH) as an additional input signal, indicating the potential of obtaining precise, temporal control over enzyme activity and anticancer drug function. Frontiers Media S.A. 2019-04-16 /pmc/articles/PMC6499185/ /pubmed/31106191 http://dx.doi.org/10.3389/fchem.2019.00243 Text en Copyright © 2019 Unger-Angel, Motiei and Margulies. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Unger-Angel, Linor Motiei, Leila Margulies, David Molecular Logic as a Means to Assess Therapeutic Antidotes |
title | Molecular Logic as a Means to Assess Therapeutic Antidotes |
title_full | Molecular Logic as a Means to Assess Therapeutic Antidotes |
title_fullStr | Molecular Logic as a Means to Assess Therapeutic Antidotes |
title_full_unstemmed | Molecular Logic as a Means to Assess Therapeutic Antidotes |
title_short | Molecular Logic as a Means to Assess Therapeutic Antidotes |
title_sort | molecular logic as a means to assess therapeutic antidotes |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499185/ https://www.ncbi.nlm.nih.gov/pubmed/31106191 http://dx.doi.org/10.3389/fchem.2019.00243 |
work_keys_str_mv | AT ungerangellinor molecularlogicasameanstoassesstherapeuticantidotes AT motieileila molecularlogicasameanstoassesstherapeuticantidotes AT marguliesdavid molecularlogicasameanstoassesstherapeuticantidotes |